RS56122B1 - Inhibitori cdc7 - Google Patents

Inhibitori cdc7

Info

Publication number
RS56122B1
RS56122B1 RS20170791A RSP20170791A RS56122B1 RS 56122 B1 RS56122 B1 RS 56122B1 RS 20170791 A RS20170791 A RS 20170791A RS P20170791 A RSP20170791 A RS P20170791A RS 56122 B1 RS56122 B1 RS 56122B1
Authority
RS
Serbia
Prior art keywords
cdc7 inhibitors
cdc7
inhibitors
Prior art date
Application number
RS20170791A
Other languages
English (en)
Inventor
Robert Dean Dally
Timothy Andrew Woods
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS56122B1 publication Critical patent/RS56122B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
RS20170791A 2013-03-14 2014-03-07 Inhibitori cdc7 RS56122B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361782798P 2013-03-14 2013-03-14
US201361789108P 2013-03-15 2013-03-15
EP14712966.2A EP2970221B1 (en) 2013-03-14 2014-03-07 Cdc7 inhibitors
PCT/US2014/021466 WO2014143601A1 (en) 2013-03-14 2014-03-07 CDC7 Inhibitors

Publications (1)

Publication Number Publication Date
RS56122B1 true RS56122B1 (sr) 2017-10-31

Family

ID=50382704

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170791A RS56122B1 (sr) 2013-03-14 2014-03-07 Inhibitori cdc7

Country Status (37)

Country Link
US (1) US9156824B2 (sr)
EP (1) EP2970221B1 (sr)
JP (1) JP6064079B2 (sr)
KR (1) KR101718645B1 (sr)
CN (1) CN105008351B (sr)
AP (1) AP2015008734A0 (sr)
AU (1) AU2014228374B2 (sr)
BR (1) BR112015020466B1 (sr)
CA (1) CA2900773C (sr)
CL (1) CL2015002530A1 (sr)
CR (1) CR20150416A (sr)
CY (1) CY1119199T1 (sr)
DK (1) DK2970221T3 (sr)
EA (1) EA027012B1 (sr)
ES (1) ES2639793T3 (sr)
GT (1) GT201500263A (sr)
HK (1) HK1212696A1 (sr)
HR (1) HRP20171151T1 (sr)
HU (1) HUE033482T2 (sr)
IL (1) IL240962B (sr)
JO (1) JO3383B1 (sr)
LT (1) LT2970221T (sr)
ME (1) ME02805B (sr)
MX (1) MX363438B (sr)
MY (1) MY188145A (sr)
NZ (1) NZ710392A (sr)
PE (1) PE20151654A1 (sr)
PH (1) PH12015502091A1 (sr)
PL (1) PL2970221T3 (sr)
PT (1) PT2970221T (sr)
RS (1) RS56122B1 (sr)
SG (1) SG11201507541PA (sr)
SI (1) SI2970221T1 (sr)
TN (1) TN2015000349A1 (sr)
TW (1) TWI622396B (sr)
UA (1) UA116125C2 (sr)
WO (1) WO2014143601A1 (sr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2906555T (pt) * 2012-10-15 2017-02-15 Pfizer Ireland Pharmaceuticals Processo para a preparação de voriconazol e análogos do mesmo
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SG11201505347VA (en) 2013-01-15 2015-08-28 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7調控劑
UY35391A (es) 2013-03-14 2014-09-30 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節物質
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN110036006B (zh) * 2016-09-22 2022-12-13 癌症研究科技有限公司 嘧啶酮衍生物的制备和用途
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108383771A (zh) * 2018-01-08 2018-08-10 华东师范大学 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
TW202028198A (zh) 2018-09-28 2020-08-01 比利時商健生藥品公司 單醯基丙三醇脂酶調節劑
BR112021005936A2 (pt) 2018-09-28 2021-06-29 Janssen Pharmaceutica Nv moduladores de monoacilglicerol lipase
US20220220125A1 (en) * 2019-04-16 2022-07-14 Janssen Pharmaceutica Nv Fused isoindolin-1-one derivatives useful as grk2 inhibitors
MX2022003819A (es) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
EP4126860A1 (en) 2020-03-26 2023-02-08 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
AU2007319580B2 (en) * 2006-10-12 2012-11-29 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
SG182187A1 (en) * 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
IL240962B (en) 2020-04-30
US20140275121A1 (en) 2014-09-18
ES2639793T3 (es) 2017-10-30
CA2900773C (en) 2018-04-17
KR20150119101A (ko) 2015-10-23
MY188145A (en) 2021-11-23
PH12015502091B1 (en) 2016-01-18
BR112015020466A2 (pt) 2017-07-18
CY1119199T1 (el) 2018-02-14
KR101718645B1 (ko) 2017-03-21
CR20150416A (es) 2015-09-16
EA027012B1 (ru) 2017-06-30
IL240962A0 (en) 2015-11-30
PE20151654A1 (es) 2015-11-12
JO3383B1 (ar) 2019-03-13
SG11201507541PA (en) 2015-10-29
UA116125C2 (uk) 2018-02-12
US9156824B2 (en) 2015-10-13
CL2015002530A1 (es) 2016-03-28
CA2900773A1 (en) 2014-09-18
LT2970221T (lt) 2017-09-11
CN105008351B (zh) 2017-03-15
BR112015020466A8 (pt) 2019-11-12
AU2014228374A1 (en) 2015-08-06
EA201591509A1 (ru) 2015-12-30
NZ710392A (en) 2020-05-29
PL2970221T3 (pl) 2017-11-30
TN2015000349A1 (en) 2017-01-03
EP2970221A1 (en) 2016-01-20
HUE033482T2 (en) 2017-12-28
TWI622396B (zh) 2018-05-01
DK2970221T3 (en) 2017-07-31
JP2016512498A (ja) 2016-04-28
BR112015020466B1 (pt) 2022-07-26
AP2015008734A0 (en) 2015-09-30
HK1212696A1 (zh) 2016-06-17
EP2970221B1 (en) 2017-06-28
PT2970221T (pt) 2017-09-22
HRP20171151T1 (hr) 2017-10-06
GT201500263A (es) 2016-03-02
PH12015502091A1 (en) 2016-01-18
SI2970221T1 (sl) 2017-08-31
AU2014228374B2 (en) 2016-09-01
MX363438B (es) 2019-03-22
JP6064079B2 (ja) 2017-01-18
TW201521726A (zh) 2015-06-16
MX2015012583A (es) 2016-01-20
ME02805B (me) 2018-01-20
WO2014143601A1 (en) 2014-09-18
CN105008351A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
HRP20190373T1 (hr) Inhibitori dnk-pk
HK1212696A1 (zh) 抑制劑
EP2968282A4 (en) HISTONDEMENTHYLASEINHIBITOREN
PL3057959T3 (pl) Inhibitory DNA-PK
HK1219475A1 (zh) 腦啡肽酶抑制劑
HK1216531A1 (zh) 新的抑制劑
IL245442A0 (en) gsk–3 inhibitors
GB201305503D0 (en) Inhibitor
GB201320835D0 (en) HIF inhibitors